Kevin Rakin (age 64) is the Executive Chairman of Elutia Inc. (ELUT), having served on the board since 2015 and assuming the role of Chairman in November 2015, later becoming Executive Chairman in June 2022.( He co-founded Elutia alongside C. Randal Mills, Ph.D., with a vision to develop regenerative medicine and biosurgical products.( In January 2024, the board determined his independence under Nasdaq rules, appointing him Lead Director.( HighCape Partners, which he co-founded in 2013 as General Partner, holds a 26% stake in Elutia.( Rakin recently traded as a Dir, 10% insider at Elutia.[userquery]

Rakin brings over 30 years of experience in life sciences finance and leadership, including prior roles as President of Shire Regenerative Medicine, Chairman and CEO of Advanced BioHealing (acquired by Shire for $750M in 2011), Executive-in-Residence at Canaan Partners, and co-founder, President, and CEO of Genaissance Pharmaceuticals (merged with Clinical Data in 2005).( He holds an MBA from Columbia University and B.Com/B.Com (Hons) from the University of Cape Town.( Current external board roles include Quantum-Si Inc., Nyxoah S.A., and others, with past service on boards like Oramed Pharmaceuticals and Histogenics Corp.(

Written by Perplexity from public sources.

Filings come from SEC EDGAR. Not investment advice.